NCT03047213 - Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2017

Primary Completion Date

October 6, 2020

Study Completion Date

November 11, 2025

Conditions

Locally Advanced Bladder Urothelial CarcinomaMetastatic Transitional Cell CarcinomaMetastatic Urothelial CarcinomaRecurrent Bladder CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage IV Bladder Urothelial Carcinoma AJCC v7

Interventions

DRUG

Sapanisertib

Given PO

Trial Locations (20)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

37204

Vanderbilt Breast Center at One Hundred Oaks, Nashville

37232

Vanderbilt University/Ingram Cancer Center, Nashville

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

60611

Northwestern University, Chicago

66205

University of Kansas Clinical Research Center, Fairway

68118

Nebraska Medicine-Village Pointe, Omaha

68123

Nebraska Medicine-Bellevue, Bellevue

68198

University of Nebraska Medical Center, Omaha

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91105

Keck Medical Center of USC Pasadena, Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH